SCHEMBL16684312

SCHEMBL16684312

[N-]=[N+]=NCC(CN=[N+]=[N-])C(=O)NN=N

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15398290 0.70 CHRM1 (0.33) —
SCHEMBL15759755 0.69 — —
SCHEMBL16677004 0.69 CA1 (0.31) —
SCHEMBL17404777 0.68 CA1 (0.38) —
SCHEMBL17274214 0.68 — —
SCHEMBL19038578 0.65 — —
SCHEMBL14252461 0.64 CPB2 (0.31) —
SCHEMBL27701090 0.64 CA2 (0.42) —
SCHEMBL27721756 0.64 CA2 (0.42) —
SCHEMBL16901679 0.63 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2607356-B1 Triazole-substituted arylamide derivatives and their use as P2x3 and /or P2x2/3 purinergic receptor antagonists HOFFMANN LA ROCHE (CH) 2015-04-29 — — EP disclosed
Send feedback